Biohaven (BHVN) Stock: Why It Jumped 27% on the FDA Filing News

Quick answer

Biohaven stock rose 26.8% to $14.90 at 11:55am ET on Oct 22, 2026, from an $11.75 close, after it said the FDA had accepted its resubmitted application for troriluzole, brand name Vyglxia, in spinocerebellar ataxia. The 8-K says the FDA considers the resubmission a complete response to its Nov 4, 2025 rejection letter, has set a user fee goal date in the first quarter of 2027, and plans to convene an advisory committee, with the date to come "in the near term." The shares traded as high as $18.39 before the open, up 56.5%, opened at $16.07 and gave back more than half of that gain by midday. Volume passed 24 million shares by noon, about 13 times the 20-day average. The biotech ETF was down 0.4%, so the move is the company's own.

Our view: Bearish through March 31, 2027, the end of the quarter in which the FDA's goal date falls. The case for the stock: the FDA treats the filing as a full response, there is no approved drug for this disease, William Blair still sees the risk and benefit as favorable, and two licensing deals bring $430 million of upfront cash at closing. The case against carries more weight. The FDA rejected troriluzole less than a year ago over possible bias in the external control comparisons that form the core of the evidence, and the resubmission adds "new positive supportive analyses," not a new controlled trial. An advisory committee puts that same question in front of outside experts, and its date is unknown. The stock has nearly doubled from the $7.60 it hit after the rejection, so a good part of an approval is already in the price, and the market sold more than half of the morning's gain by late morning. We would move off Bearish if the FDA's briefing documents for the advisory committee accept the external control approach, if the committee votes in favor, or if the SK Biopharmaceuticals deal closes and extends the cash runway well into 2028. This is a view on direction over that window, not a recommendation to trade the stock.

Biohaven daily closing price from Sep 9 to Oct 22, 2026, with the Sep 10 partial clinical hold drop, the Oct 16 low and the Oct 22 jump marked

Key takeaways

Biohaven rose 26.8% to $14.90 at 11:55am ET on Oct 22, 2026, from an $11.75 close, after an 8-K said the FDA accepted its resubmitted application for troriluzole (Vyglxia) in spinocerebellar ataxia, with a goal date in the first quarter of 2027.
The stock traded as high as $18.39 in premarket trading, up 56.5%, opened at $16.07 and gave back more than half of that gain by midday.
The FDA also plans an advisory committee meeting, date not yet set; it rejected the drug on Nov 4, 2025, citing the potential for bias in the real-world evidence and external control comparisons behind the filing.
Biohaven has two licensing deals worth $430 million in upfront cash at closing, against $270.5 million of cash on June 30 and quarterly operating costs above $120 million.
Our view is Bearish through March 31, 2027: the resubmission rests on new analyses of the same kind of evidence the FDA rejected, and the stock has already doubled from its post-rejection low.

Table of contents

Oct 22, 2026: the FDA accepts the resubmission, and the stock gives back half the gain
The history: a rejection, a cost cut and two licensing deals
The bull case
The risks
What comes next

Oct 22, 2026: the FDA accepts the resubmission, and the stock gives back half the gain

The 8-K came out before the open. The stock traded at $11.60 at 4:00am, reached $18.39 at about 7:50am, up 56.5%, and was $16.09 just before the bell. It opened at $16.07, touched $16.54 at about 9:35am, up 40.8%, and drifted lower all morning to $14.60 at about 11:45am. At 11:55am it was $14.90, up 26.8%. BioSpace reported the shares at $15.41 at 10:40am.

What lifted it:

The filing is back under review. The FDA considers the resubmission a complete response to the Nov 4, 2025 action letter and assigned a goal date in the first quarter of 2027. Our explainer on how PDUFA dates work covers what that date does and does not promise.
New analyses. The resubmission "included new positive supportive analyses." Biohaven has not described them publicly.
An analyst who still likes the drug. William Blair wrote that "the Vyglxia AdCom will be the most de-risking event here" and said it continues to see the risk and benefit as favorable in a disease with no approved therapy, BioSpace reported.

What held it back:

An advisory committee. The FDA wants outside input before deciding, which keeps the outcome open. The date has not been set.
The same evidence question. BioSpace reported that the 2025 rejection cited "issues that can be inherent to real-world evidence and external control studies including potential bias," and that FDA feedback before the filing called for a large treatment effect to overcome the biases of an externally controlled trial. Biohaven says its results met that bar.

The path of the day:

Point	Price	Change from Oct 21 close
Oct 21 close	$11.75
Premarket high, about 7:50am	$18.39	+56.5%
Open, 9:30am	$16.07	+36.8%
Session high, about 9:35am	$16.54	+40.8%
Session low, about 11:45am	$14.60	+24.3%
11:55am	$14.90	+26.8%
SPDR S&P Biotech ETF (XBI), 11:55am	$152.15	-0.4%

Bar chart of Biohaven's price on Oct 22, 2026: Oct 21 close $11.75, premarket high $18.39, open $16.07, session high $16.54, session low $14.60, 11:55am $14.90

For other biotech names moving on FDA news, see our pages on Disc Medicine, Rapport Therapeutics and today's biggest stock moves.

After the move, RSI(14) stood at 65, the shares sat 10% above their 50-day average and 23% above their 200-day average, volume ran 12.8 times its 20-day average of 1.9 million shares, and the stock was 20% below its 52-week high of $18.57.

The history: a rejection, a cost cut and two licensing deals

Troriluzole's evidence comes from a three-year study that compared treated patients with a natural history database. BioSpace reported that the Phase 3 study missed its primary endpoint on a modified ataxia rating scale, while comparisons with the natural history controls showed 50% to 70% slower decline at the 200 mg dose. After the Nov 4, 2025 rejection the shares fell nearly 45% to $7.60, and Biohaven cut research spending.

Since then:

Aug 26, 2026: Biohaven licensed its Kv7 epilepsy drug opakalim (BHV-7000) to SK Biopharmaceuticals for $400 million upfront, $350 million at closing and $50 million a year later, plus up to $150 million in milestones. Closing needs antitrust clearance.
Sept 4, 2026: The FDA placed a partial clinical hold on BHV-7000 that pauses new enrollment until more animal data on a metabolite are in. The stock fell 14.7% on Sept 10, the day the 8-K was filed, and RBC cut its rating to Sector Perform on Sept 8.
Oct 8, 2026: Biohaven licensed its IgG degrader portfolio in Japan and parts of Asia to Ono Pharmaceutical for $80 million at closing and $20 million on a later milestone.

Cash, equivalents, marketable securities and restricted cash were about $270.5 million on June 30, 2026. Second-quarter research spending was $100.8 million and general and administrative costs $24.1 million. Our guide on how to estimate cash runway shows how to set those numbers against the cash coming in.

The bull case

No approved therapy. Spinocerebellar ataxia has no FDA-approved treatment, and advisory committees weigh unmet need.
A formal path. Acceptance as a complete response means the FDA will rule within a set window, with outside experts heard first.
Cash on the way. The two licensing deals bring $430 million at closing, more than the cash on hand in June.
Analyst targets. The average target is about $24.67, set before Thursday, with a range of $11 to $48.

The risks

Same kind of evidence. The new material is supportive analyses, not a new controlled trial, and the FDA's stated concern was bias in that design.
An open-ended committee. Without a date, the stock carries the event risk for weeks or months. Our explainer on probability-weighted valuation for binary events shows how to price that kind of yes or no outcome.
Spending. Quarterly operating costs above $120 million in the second quarter mean the licensing cash matters, and the larger deal has not closed.
The price already moved. The shares have nearly doubled from the post-rejection low, and the day's fade shows sellers waiting near $16 to $18.

What comes next

The advisory committee date and briefing documents. The FDA's own review posted before the meeting is usually the first clear read on its view.
The committee vote.
The FDA decision, in the first quarter of 2027.
Third-quarter results, expected around Nov 9. Cash, the status of the SK Biopharmaceuticals closing and spending plans.

Frequently asked questions

Why is Biohaven stock up today?

Biohaven said in an 8-K on Oct 22 that the FDA accepted its resubmitted new drug application for troriluzole, brand name Vyglxia, in spinocerebellar ataxia, treats it as a complete response to the November 2025 rejection, and set a goal date in the first quarter of 2027. The shares were $14.90 at 11:55am ET, up 26.8%.

When is the FDA decision on troriluzole?

The FDA assigned a user fee goal date in the first quarter of 2027. Biohaven did not give an exact date. The FDA also plans to convene its Peripheral and Central Nervous System Advisory Committee, with the date to come in the near term.

Why did the FDA reject troriluzole before?

The FDA issued a complete response letter on Nov 4, 2025. BioSpace reported that it cited issues that can be inherent to real-world evidence and external control studies, including potential bias, and that earlier FDA feedback called for a large treatment effect to overcome the biases of an externally controlled trial.

What is spinocerebellar ataxia?

Spinocerebellar ataxia is a group of inherited diseases that damage the cerebellum and cause worsening loss of coordination. There is no FDA-approved treatment for it in the United States, which is why the advisory committee's view of the risk and benefit will matter.

How much cash does Biohaven have?

Biohaven reported about $270.5 million of cash, equivalents, marketable securities and restricted cash on June 30, 2026. It expects $350 million at the closing of its SK Biopharmaceuticals license, which needs antitrust clearance, and $80 million at the closing of its Ono Pharmaceutical license.

What is the analyst price target for Biohaven?

The average analyst target is about $24.67, with targets from $11 to $48. William Blair said the advisory committee 'will be the most de-risking event here' and still sees the drug's risk and benefit as favorable.

Sources

Article details

By James Whitfield, Head of Equity Research, Dombey Capital

Published October 22, 2026 · 6 min read · Options and Catalysts